Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Serge Belanger
NDM
Serge Belanger
Needham
Wall Street Analyst
★★★☆☆
#1639
on 13Foresight · ranked by our own returns
42%
Success Rate
+2.2%
Average Return
10 of 24 calls profitable · +0.9% vs benchmark
📈 Across the calls we could measure, roughly 42% of Serge Belanger's ratings turned a profit when each position was held for 1 year — averaging +2.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

152 Buy 33 Hold 0 Sell
Serge's Stock Coverage 27 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CYTK
Cytokinetics
 Jun 16, 2026 BUY Strong Buy
+9.9% avg upside
36 analysts
$102.00
30.56% Upside
 +5.0%
MLTX
MoonLake Immunotherapeutics
 Jun 08, 2026 BUY Strong Buy
+51.0% avg upside
20 analysts
$30.00
56.26% Upside
 +6.6%
MANE
Veradermics, Incorporated
 Jun 02, 2026 BUY Strong Buy
+34.8% avg upside
6 analysts
$136.00
48.02% Upside
 ·
HRTX
Heron Therapeutics
 Jun 02, 2026 HOLD Strong Buy
+6864.0% avg upside
21 analysts
 — -4.4%
OCS
Oculis Holding
 Jun 01, 2026 BUY Strong Buy
+240.7% avg upside
11 analysts
$38.00
236.24% Upside
 -21.1%
TRVI
Trevi Therapeutics
 May 20, 2026 BUY Strong Buy
+22.4% avg upside
16 analysts
$23.00
40.52% Upside
 ·
CRMD
Cormedix
 May 14, 2026 BUY Strong Buy
+72.9% avg upside
13 analysts
$15.00
73.09% Upside
 +7.7%
OMER
Omeros
 May 14, 2026 HOLD Buy
+113.6% avg upside
14 analysts
 — -27.4%
VRCA
Verrica Pharmaceuticals
 May 13, 2026 HOLD Strong Buy
+213.5% avg upside
8 analysts
 — -10.8%
ESPR
Esperion
 May 12, 2026 HOLD Buy
+696.9% avg upside
22 analysts
 — +0.6%
COLL
Collegium Pharmaceutical
 May 12, 2026 BUY Strong Buy
+25.5% avg upside
8 analysts
$56.00
66.28% Upside
 -5.3%
LQDA
Liquidia Technologies
 May 11, 2026 BUY Strong Buy
-26.3% avg upside
15 analysts
$70.00
1.88% Upside
 +27.9%
AMPH
Amphastar Pharmaceuticals
 May 08, 2026 HOLD Hold
+39.4% avg upside
11 analysts
 — ·
XENE
Xenon
 May 08, 2026 BUY Strong Buy
+18.6% avg upside
28 analysts
$78.00
46.56% Upside
 -7.2%
NAMS
NewAmsterdam Pharma Company
 May 07, 2026 BUY Strong Buy
+54.8% avg upside
18 analysts
$48.00
59.26% Upside
 -14.4%
ARQT
Arcutis Biotherapeutics
 May 07, 2026 BUY Strong Buy
+50.8% avg upside
14 analysts
$36.00
37.22% Upside
 +24.2%
BCRX
BioCryst
 May 06, 2026 BUY Strong Buy
+102.2% avg upside
24 analysts
$16.00
78.85% Upside
 -4.5%
VRDN
Viridian Therapeutics
 May 05, 2026 BUY Strong Buy
+102.9% avg upside
32 analysts
$32.00
91.42% Upside
 -14.1%
EOLS
Evolus
 May 05, 2026 HOLD Strong Buy
+114.8% avg upside
9 analysts
 — +5.8%
OCUL
Ocular Therapeutix
 May 05, 2026 BUY Strong Buy
+153.7% avg upside
21 analysts
$18.00
86.79% Upside
 -7.4%
PCRX
Pacira Pharmaceuticals
 May 01, 2026 BUY Buy
+72.5% avg upside
21 analysts
$32.00
41.32% Upside
 -5.9%
CLSDQ
Clearside Biomedical
 Dec 23, 2025 HOLD Hold
+139900.0% avg upside
10 analysts
 — -63.9%
CALC
CalciMedica
 Oct 28, 2022 HOLD Buy
+3372.0% avg upside
9 analysts
 — -61.8%
AKBA
Akebia Therapeutics
 Oct 28, 2022 HOLD Strong Buy
+864.1% avg upside
16 analysts
 — +223.1%
GREE
Greenidge Generation Holdings
 Nov 05, 2021 BUY Hold
+538.4% avg upside
5 analysts
$22.00
1319.33% Upside
 ·
EVFM
Evofem Biosciences
 Jun 26, 2017 HOLD Buy
+259948.4% avg upside
8 analysts
 — ·
CYTOF
Altamira Therapeutics
 Aug 19, 2016 BUY Strong Buy
+21133.5% avg upside
4 analysts
$5.00
4955.55% Upside
 ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Serge Belanger — Frequently Asked Questions
How accurate are Serge Belanger's stock ratings?
Based on the calls 13Foresight could measure, about 42% of Serge's ratings were profitable over a one-year hold, with an average return of +2.2% per rating, or +0.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Serge ranked on 13Foresight?
Serge Belanger is currently ranked #1639 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Serge cover?
Serge most recently has ratings on CYTK, MLTX, MANE, HRTX, OCS, TRVI, CRMD, OMER, VRCA, ESPR, COLL, LQDA and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.